NY-EMPIRE-STATE-REALTY
Be an ESB VIP. The Empire State Building (ESB) announced today its new ambassador program for locals who host guests in New York City and superfans of its world-famous Observatory Experience. Visitors earn points in the loyalty program for each ticket purchased on the ESB website for the 86th and 102nd Floor Observatories and redeem them for complimentary experiences and collectibles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213973067/en/
Rewards to include exclusive NFTs, complimentary tickets, and special experiences. (Photo: Business Wire)
“Each visit to the Empire State Building is unique, and we made it easier for our loyal locals who bring their guests and our superfans to take in our reimagined Observatory’s exhibits and unparalleled views time and time again,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “We want to show our fans our appreciation for their loyalty and offer exclusive access to premium, authentic experiences and the best views from the heart of New York City.”
Members will progress through four tiers and collect rewards at each tier which include:
-
Ambassador (Unlocked at 0-439 points)
- Has registered for the program
- Not yet eligible for any benefits
-
Bronze Ambassador (Unlocked at 440 points)
- Inclusion in our Ambassadors’ Newsletter
- One ticket to the 86th Floor Observatory
- One lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity appearances events. Non-transferable.
-
Silver Ambassador (Unlocked at 880 points)
- Inclusion in our Ambassadors’ Newsletter
- One additional ticket to the 86th Floor Observatory
- One additional lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
-
Gold Ambassador (Unlocked at 1,320 points)
- Inclusion in our Ambassadors’ Newsletter
- Two tickets to the 86th and 102nd Floor Observatories
- Two tickets to a scheduled Saturday morning Sunrise Experience
- Two entries to the coveted annual Empire State Building Run-Up (assignable to a family member or friend) or lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
-
Platinum Ambassador (Unlocked at 1,760 points)
- Inclusion in our Ambassadors’ Newsletter
- Four tickets to the 86th and 102nd Floor Observatories
- Four tickets to a scheduled Saturday morning Sunrise Experience
- One entry to the coveted annual Empire State Building Run-Up (assignable to a family member or friend).
- Entry for access for four (4) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable
Each new member of the Ambassador Program will receive a custom NFT upon signup. For each tier achieved, members will receive additional custom NFTs, developed and distributed in partnership with Uptop, which feature the “World’s Most Famous Building” against an Art Deco backdrop in the tier’s respective metallic tone. The exclusive NFTs serve as a digital keepsake and a key to unlock their personalized rewards.
Visitors who join the Ambassador Program who purchased tickets on or after Feb. 1, 2024 will automatically receive points and the new member NFT for their last purchase retroactively. Points and status acquired remain until redemptions and do not expire.
The Empire State Building Observatory recently underwent a $165 million reimagination that includes a dedicated visitor entrance, an immersive museum with nine galleries, brand new bespoke Observatory Host uniforms, and iconic 86th and 102nd Floor Observatories. The reimagined Observatory Experience was recently voted the number one attraction in the U.S. by Tripadvisor travelers for two consecutive years.
Registration for the Ambassador Program can be found here.
Hi-res imagery can be found here. More information about the Empire State Building Observatory can be found online.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the US for the second year in a row in Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
Source: Empire State Realty Trust, Inc.
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213973067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom